SA
Create Free Alerts
Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference
defenseworld.net

Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference

Executives from Esperion Therapeutics (NASDAQ: ESPR) highlighted accelerating revenue growth, plans to expand its commercial footprint, and details of a pending acquisition during remarks at the Citizens Life Sciences Conference in Miami, coming a day after the company reported earnings. 2025 results and momentum entering 2026 Chief Executive Officer Sheldon Koenig said Esperion delivered what he

Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.25
defenseworld.net

Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.25

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
globenewswire.com

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

–  Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth –

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
businesswire.com

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ANN ARBOR, Mich. & HENDERSON, Nev.--(BUSINESS WIRE)-- #CHF--Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis. Under the terms of the agreement, Esperion will acquire Corstasis, which developed and is commercia.

Principal Financial Group Inc. Trims Stake in Esperion Therapeutics, Inc. $ESPR
defenseworld.net

Principal Financial Group Inc. Trims Stake in Esperion Therapeutics, Inc. $ESPR

Principal Financial Group Inc. lessened its position in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) by 51.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 190,056 shares of the biopharmaceutical company's stock after selling 203,234 shares during the quarter. Principal Financial Group

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
globenewswire.com

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem's Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance